Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Mark Lovern"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1784-1794 (2023)
Abstract Pemigatinib is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR)1–3 with efficacy in patients with previously treated, advanced/metastatic cholangiocarcinoma (CCA) with FGFR2 alterations. A previously develope
Externí odkaz:
https://doaj.org/article/33244a1ee9ce4d65853a51e47708724f
Autor:
Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still, Ralph A. Tripp
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show pro
Externí odkaz:
https://doaj.org/article/d191ef95cc404745a8ce8416434d12ad
Autor:
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Parul Patel, Katy P. Moore, Ciara S. Seal, Amy G. Cutrell, Ronald D. D'Amico, Paul D. Benn, Raphael J. Landovitz, Mark A. Marzinke, William R. Spreen, Susan L. Ford
Publikováno v:
British journal of clinical pharmacology, vol 88, iss 10
AimTo characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic factors with pharmacokinetic variability.MethodsAnalyses were implemented in NONMEM and R. Co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819f73d915c1922d8d7901fda918bc08
https://doi.org/10.1111/bcp.15439
https://doi.org/10.1111/bcp.15439
Autor:
Dan Bloomfield, Naab M. Al‐Saady, Debra Freedholm, Sara Coulter, Norman E. Lepor, Xiaohui Wang, Nancy Widener, Mark Lovern, Constance Cullen, Byungdoo Alexander Yi, Emilie Simard
Publikováno v:
Journal of Thrombosis and Haemostasis. 20:307-315
Background Factor XI (FXI) inhibition offers the promise of hemostasis-sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2022a6f5c2560d66f2ddc2a3e2cc7c
https://doi.org/10.1111/jth.15577
https://doi.org/10.1111/jth.15577
Autor:
Fred D. Sancilio, Mark Lovern, Kathy Blahunka, Robert J. Hogan, Rajiv Balyan, Jackelyn Murray, Ralph A. Tripp, Richard Still, David E. Martin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Scientific Reports
Scientific Reports
Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b036f5e8a1dc0a37422a223fe85aae7
https://doaj.org/article/d191ef95cc404745a8ce8416434d12ad
https://doaj.org/article/d191ef95cc404745a8ce8416434d12ad
Autor:
Richard Franzese, Todd Riccobene, Timothy Carrothers, Manoli Vourvahis, Erica Winter, Mark Lovern, Lynn McFadyen
Publikováno v:
Clinical pharmacology and therapeutics. 113(1)
Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor combination developed to treat serious Gram-negative bacterial infections; approved indications include complicated urinary tract infection, complicated intra-abdominal infection, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48ec9fb05f1df6e87a104970e53f8c41
https://pubmed.ncbi.nlm.nih.gov/36239478
https://pubmed.ncbi.nlm.nih.gov/36239478
Autor:
Manoli Vourvahis, Timothy J. Carrothers, Lynn McFadyen, John S. Bradley, Mark Lovern, Todd Riccobene, Susan Raber, Richard C. Franzese, Kenny J. Watson, Phylinda L. S. Chan
Publikováno v:
Clinical pharmacology and therapeutics, vol 111, iss 3
Increasing prevalence of infections caused by antimicrobial-resistant gram-negative bacteria represents a global health crisis, and while several novel therapies that target various aspects of antimicrobial resistance have been introduced in recent y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::596328c6515dcf6576a4e0e2e86d82c2
https://escholarship.org/uc/item/456322xv
https://escholarship.org/uc/item/456322xv
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b771dfd5a4c0bb245b4056a336ea1a1e
https://doi.org/10.1016/j.jaad.2022.06.197
https://doi.org/10.1016/j.jaad.2022.06.197
Autor:
Ralph A. Tripp, Jackelyn Murray, Kathy Blahunka, Robert J. Hogan, Fred Sancillo, Mark Lovern, Rajiv Balyan, Richard Still, David E. Martin
Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9c444d144071120febe1809470085d0
https://doi.org/10.1101/2021.05.21.445119
https://doi.org/10.1101/2021.05.21.445119
Autor:
Angela K Talley, Todd Riccobene, Jianguo Li, Timothy J. Carrothers, Paul Newell, Shampa Das, Mark Lovern, Margaret Tawadrous
Publikováno v:
Antimicrob Agents Chemother
An extensive clinical development program (comprising two phase 2 and five phase 3 trials) has demonstrated the efficacy and safety of ceftazidime-avibactam in the treatment of adults with complicated intra-abdominal infection (cIAI), complicated uri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd21b60c3152c11aa31dc8571ae3b04
https://pubmed.ncbi.nlm.nih.gov/32015049
https://pubmed.ncbi.nlm.nih.gov/32015049